Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

David S. Ettinger, Dianne M. Finkelstein, Martin D. Abeloff, Yuang Chi Chang, Thomas J. Smith, Martin M. Oken, John C. Ruckdeschel

Research output: Contribution to journalArticlepeer-review

Abstract

Fifty-four evaluable patients with SCLC previously treated with chemotherapy received either N-methylformamide or spirogermanium. There was one partial response to N-methylformamide. The median survival times for patients treated with N-MF and spirogermanium were 11.7 and 12.6 weeks respectively. Five patients treated with N-MF experienced severe toxicity while four patients treated with spirogermanium experienced severe and life-threatening toxicity.

Original languageEnglish (US)
Pages (from-to)183-185
Number of pages3
JournalInvestigational New Drugs
Volume8
Issue number2
DOIs
StatePublished - May 1 1990

Keywords

  • n-methylformamide
  • small cell lung cancer
  • spirogermanium

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer'. Together they form a unique fingerprint.

Cite this